A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer

Abstract excerpt

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is among the cancer types with poorest prognosis and survival rates primarily due to resistance to standard-of-care therapies, including gemcitabine (GEM) and olaparib. Particularly, wild-type (wt)BRCA tumours, the most prevalent in PDAC, are more resistant to DNA-targeting agents like olaparib, restraining their clinical application. Recently, we disclosed a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy